Top

International Urogynecology Journal

Published in:

01-07-2009 | Original Article

Efficacy and tolerability of fesoterodine in women with overactive bladder

Authors: Peter K. Sand, Jon D. Morrow, Tamara Bavendam, Dana L. Creanga, Victor W. Nitti

Published in: International Urogynecology Journal | Issue 7/2009

Abstract

Introduction and hypothesis

We assessed fesoterodine efficacy and tolerability in women with overactive bladder (OAB).

Methods

This post hoc analysis of pooled data from two clinical trials included 1,548 women with OAB randomized to placebo, fesoterodine 4 or 8 mg, or tolterodine extended release (ER) 4 mg (in 1 trial) for 12 weeks. Subjects completed 3-day bladder diaries at baseline and weeks 2 and 12 and rated Treatment Response at weeks 2 and 12.

Results

By weeks 2 and 12, all active-treatment groups showed significant improvements in all five bladder diary variables assessed and greater Treatment Response rates vs placebo. Fesoterodine 8 mg was significantly more efficacious than fesoterodine 4 mg and tolterodine ER in improving urgency urinary incontinence episodes and continent days per week. The most common adverse events were dry mouth and constipation, which were predominately mild or moderate.

Conclusions

Fesoterodine is efficacious and well tolerated in women with OAB.

Irwin DE, Milsom I, Hunskaar S, Reilly K, Kopp Z, Herschorn S et al (2006) Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 50:1306–15PubMedCrossRef

Hu TW, Wagner TH, Bentkover JD, Leblanc K, Zhou SZ, Hunt T (2004) Costs of urinary incontinence and overactive bladder in the United States: a comparative study. Urology 63:461–5PubMedCrossRef

Stach-Lempinen B, Sintonen H, Kujansuu E (2004) The relationship between clinical parameters and health-related quality of life as measured by the 15D in incontinent women before and after treatment. Acta Obstet Gynecol Scand 83:983–8PubMedCrossRef

van der Vaart CH, de Leeuw JR, Roovers JP, Heintz AP (2002) The effect of urinary incontinence and overactive bladder symptoms on quality of life in young women. BJU Int 90:544–9PubMedCrossRef

Coyne KS, Sexton CC, Irwin DE, Kopp ZS, Kelleher CJ, Milsom I (2008) The impact of overactive bladder, incontinence and other lower urinary tract symptoms on quality of life, work productivity, sexuality and emotional well-being in men and women: results from the EPIC study. BJU Int 101:1388–95PubMedCrossRef

Coyne KS, Margolis MK, Jumadilova Z, Bavendam T, Mueller E, Rogers R (2007) Overactive bladder and women’s sexual health: what is the impact? J Sex Med 4:656–66PubMedCrossRef

Chapple CR, Khullar V, Gabriel Z, Muston D, Bitoun CE, Weinstein D (2008) The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. Eur Urol 54:543–62PubMedCrossRef

Rogers R, Bachmann G, Jumadilova Z, Sun F, Morrow JD, Guan Z et al (2008) Efficacy of tolterodine on overactive bladder symptoms and sexual and emotional quality of life in sexually active women. Int Urogynecol J Pelvic Floor Dysfunct 19:1551–7PubMedCrossRef

Elinoff V, Bavendam T, Glasser DB, Carlsson M, Eyland N, Roberts R (2006) Symptom-specific efficacy of tolterodine extended release in patients with overactive bladder: the IMPACT trial. Int J Clin Pract 60:745–51PubMedCrossRef

10.

Khullar V, Hill S, Laval K-U, Schiotz HA, Jonas U, Versi E (2004) Treatment of urge-predominant mixed urinary incontinence with tolterodine extended release: a randomized, placebo-controlled trial. Urology 64:269–75PubMedCrossRef

11.

Michel MC (2008) Fesoterodine: a novel muscarinic receptor antagonist for the treatment of overactive bladder syndrome. Expert Opin Pharmacother 9:1787–96PubMedCrossRef

12.

Malhotra B, Guan Z, Wood N, Gandelman K (2008) Pharmacokinetic profile of fesoterodine. Int J Clin Pharmacol Ther 46:556–63PubMed

13.

Sachse R, Cawello W, Horstmann R (2004) Safety, tolerability and pharmacokinetics of fesoterodine after co-treatment with the potent cytochrome P450 3A4 inhibitor ketoconazole. Paper presented at International Continence Society Annual Meeting, Paris, France, August 25–27, 2004

14.

Chapple C, van Kerrebroeck P, Tubaro A, Haag-Molkenteller C, Forst H-T, Massow U et al (2007) Clinical efficacy, safety, and tolerability of once-daily fesoterodine in subjects with overactive bladder. Eur Urol 52:1204–12PubMedCrossRef

15.

Nitti V, Dmochowski R, Sand P, Forst H-T, Haag-Molkenteller C, Massow U et al (2007) Efficacy, safety, and tolerability of fesoterodine in subjects with overactive bladder. J Urol 178:2488–94PubMedCrossRef

16.

Khullar V, Rovner ES, Dmochowski R, Nitti V, Wang J, Guan Z (2008) Fesoterodine dose response in subjects with overactive bladder syndrome. Urology 71:839–43PubMedCrossRef

17.

Kelleher CJ, Tubaro A, Wang JT, Kopp Z (2008) Impact of fesoterodine on quality of life: pooled data from two randomized trials. BJU Int 102:56–61PubMedCrossRef

18.

Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U et al (2003) The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology 61:37–49PubMedCrossRef

19.

Colman S, Chapple C, Nitti V, Haag-Molkenteller C, Hastedt C, Massow U (2008) Validation of treatment benefit scale for assessing subjective outcomes in treatment of overactive bladder. Urology 72:803–07PubMedCrossRef

20.

Cohen J (1988) Statistical power analysis for the behavioral sciences. Lawrence Erlbaum, Hillsdale

21.

Herschorn S, Heesakkers J, Castro-Diaz D, Wang JT, Brodsky M, Guan Z (2008) Effects of tolterodine extended release on patient perception of bladder condition and overactive bladder symptoms. Curr Med Res Opin 24:3513–21PubMedCrossRef

22.

Sussman DO, Kraus SR, Carlsson M, Guan Z (2007) Onset of efficacy of tolterodine extended release in patients with overactive bladder. Curr Med Res Opin 23:777–81PubMedCrossRef

23.

Irwin DE, Abrams P, Milsom I, Kopp Z, Reilly K (2008) Understanding the elements of overactive bladder: questions raised by the EPIC study. BJU Int 101:1381–7PubMedCrossRef

24.

Homma Y, Koyama N (2006) Minimal clinically important change in urinary incontinence detected by a quality of life assessment tool in overactive bladder syndrome with urge incontinence. Neurourol Urodyn 25:228–35PubMedCrossRef

25.

Cardozo L, Lisec M, Millard R, van Vierssen Trip O, Kuzmin I, Drogendijk TE et al (2004) Randomized, double-blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder. J Urol 172:1919–24PubMedCrossRef

26.

Corcos J, Casey R, Patrick A, Andreou C, Miceli PC, Reiz JL et al (2006) A double-blind randomized dose-response study comparing daily doses of 5, 10 and 15 mg controlled-release oxybutynin: balancing efficacy with severity of dry mouth. BJU Int 97:520–7PubMedCrossRef

27.

Hill S, Khullar V, Wyndaele JJ, Lheritier K (2006) Dose response with darifenacin, a novel once-daily M3 selective receptor antagonist for the treatment of overactive bladder: results of a fixed dose study. Int Urogynecol J Pelvic Floor Dysfunct 17:239–47PubMedCrossRef

28.

Chapple CR, Van Kerrebroeck PE, Junemann KP, Wang JT, Brodsky M (2008) Comparison of fesoterodine and tolterodine in patients with overactive bladder. BJU Int 102:1128–32PubMedCrossRef

29.

Coyne KS, Elinoff V, Gordon DA, Deng DY, Brodsky M, Glasser DB et al (2008) Relationships between improvements in symptoms and patient assessments of bladder condition, symptom bother and health-related quality of life in patients with overactive bladder treated with tolterodine. Int J Clin Pract 62:925–31PubMedCrossRef

30.

Abrams P, Artibani W, Gajewski JB, Hussain I (2006) Assessment of treatment outcomes in patients with overactive bladder: importance of objective and subjective measures. Urology 68(suppl 2A):17–28PubMedCrossRef

Title: Efficacy and tolerability of fesoterodine in women with overactive bladder
Authors: Peter K. Sand
Jon D. Morrow
Tamara Bavendam
Dana L. Creanga
Victor W. Nitti
Publication date: 01-07-2009
Publisher: Springer-Verlag
Published in: International Urogynecology Journal / Issue 7/2009
Print ISSN: 0937-3462
Electronic ISSN: 1433-3023
DOI: https://doi.org/10.1007/s00192-009-0857-2

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Efficacy and tolerability of fesoterodine in women with overactive bladder

Abstract

Introduction and hypothesis

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Introduction and hypothesis

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 7/2009

Uterine prolapse after pelvic trauma: case report and literature review

Irritative symptoms are the main predictor of satisfaction rate in women after transobturator tape procedures

Urgency-free time interval as primary endpoint for evaluating the outcome of a randomized OAB treatment

Factors predictive of outcome in tension-free vaginal tape procedure for urinary stress incontinence in a teaching hospital

Gluteo-vaginal fistula after posterior intravaginal slingplasty: a case report

Pelvic floor muscle function in women presenting with pelvic floor disorders